[Antilipemic effect of bezafibrate in patients with hyperlipoproteinemia type IV]. 1985

K Chwistecki, and M Mrukowicz, and E Kopel

UI MeSH Term Description Entries
D006953 Hyperlipoproteinemia Type IV A hypertriglyceridemia disorder, often with autosomal dominant inheritance. It is characterized by the persistent elevations of plasma TRIGLYCERIDES, endogenously synthesized and contained predominantly in VERY-LOW-DENSITY LIPOPROTEINS (pre-beta lipoproteins). In contrast, the plasma CHOLESTEROL and PHOSPHOLIPIDS usually remain within normal limits. Hyperprebetalipoproteinemia,Hypertriglyceridemia, Familial,Carbohydrate Inducible Hyperlipemia,Carbohydrate-Inducible Hyperlipemia,Familial Hyperlipoproteinemia Type 4,Familial Type IV Hyperlipoproteinemia,Hyper prebeta lipoproteinemia,Hyperlipoproteinemia, Type IV,Carbohydrate Inducible Hyperlipemias,Carbohydrate-Inducible Hyperlipemias,Familial Hypertriglyceridemia,Hyperlipemia, Carbohydrate Inducible,Hyperlipemia, Carbohydrate-Inducible,Hyperlipemias, Carbohydrate Inducible,Hyperlipemias, Carbohydrate-Inducible,Hyperlipoproteinemias, Type IV,Inducible Hyperlipemia, Carbohydrate,Inducible Hyperlipemias, Carbohydrate,Type IV Hyperlipoproteinemia,Type IV Hyperlipoproteinemias,Type IV, Hyperlipoproteinemia
D008077 Lipoproteins, LDL A class of lipoproteins of small size (18-25 nm) and light (1.019-1.063 g/ml) particles with a core composed mainly of CHOLESTEROL ESTERS and smaller amounts of TRIGLYCERIDES. The surface monolayer consists mostly of PHOSPHOLIPIDS, a single copy of APOLIPOPROTEIN B-100, and free cholesterol molecules. The main LDL function is to transport cholesterol and cholesterol esters to extrahepatic tissues. Low-Density Lipoprotein,Low-Density Lipoproteins,beta-Lipoprotein,beta-Lipoproteins,LDL(1),LDL(2),LDL-1,LDL-2,LDL1,LDL2,Low-Density Lipoprotein 1,Low-Density Lipoprotein 2,LDL Lipoproteins,Lipoprotein, Low-Density,Lipoproteins, Low-Density,Low Density Lipoprotein,Low Density Lipoprotein 1,Low Density Lipoprotein 2,Low Density Lipoproteins,beta Lipoprotein,beta Lipoproteins
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000924 Anticholesteremic Agents Substances used to lower plasma CHOLESTEROL levels. Cholesterol Inhibitors,Hypocholesteremic Agents,Anticholesteremic Drugs,Anticholesteremics,Inhibitors, Cholesterol,Agents, Anticholesteremic,Agents, Hypocholesteremic,Drugs, Anticholesteremic
D001629 Bezafibrate An antilipemic agent that lowers CHOLESTEROL and TRIGLYCERIDES. It decreases LOW DENSITY LIPOPROTEINS and increases HIGH DENSITY LIPOPROTEINS. Azufibrat,BM-15.075,Befibrat,Beza-Lande,Beza-Puren,Bezabeta,Bezacur,Bezafibrat PB,Bezafisal,Bezalip,Bezamerck,Béfizal,Cedur,Difaterol,Eulitop,Lipox,Reducterol,Regadrin B,Sklerofibrat,Solibay,durabezur,BM 15.075,BM15.075,Beza Lande,Beza Puren
D014280 Triglycerides An ester formed from GLYCEROL and three fatty acid groups. Triacylglycerol,Triacylglycerols,Triglyceride

Related Publications

K Chwistecki, and M Mrukowicz, and E Kopel
March 1992, Polskie Archiwum Medycyny Wewnetrznej,
K Chwistecki, and M Mrukowicz, and E Kopel
January 1983, Polskie Archiwum Medycyny Wewnetrznej,
K Chwistecki, and M Mrukowicz, and E Kopel
January 1979, Acta medica Austriaca,
K Chwistecki, and M Mrukowicz, and E Kopel
February 1976, Polskie Archiwum Medycyny Wewnetrznej,
K Chwistecki, and M Mrukowicz, and E Kopel
January 1985, Clinical and experimental rheumatology,
K Chwistecki, and M Mrukowicz, and E Kopel
April 1997, European journal of medical research,
K Chwistecki, and M Mrukowicz, and E Kopel
March 1986, Polski tygodnik lekarski (Warsaw, Poland : 1960),
Copied contents to your clipboard!